bond laboratories inc (BNLB:OTC US)
bond laboratories inc (BNLB) Snapshot
|
Open
$0.11
|
Previous Close
$0.11
|
|
|
Day High
$0.11
|
Day Low
$0.10
|
|
|
52 Week High
08/29/12 - $0.14
|
52 Week Low
05/29/12 - $0.06
|
|
|
Market Cap
8.2M
|
Average Volume 10 Days
195.1K
|
|
|
EPS TTM
$0.03
|
Shares Outstanding
77.8M
|
|
|
EX-Date
--
|
P/E TM
3.5x
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
bond laboratories inc (BNLB) Related Businessweek News
No Related Businessweek News Foundbond laboratories inc (BNLB) Details
Bond Laboratories, Inc., through its subsidiaries, provides nutritional supplements for health conscious consumers in the United States. It manufactures and distributes a range of nutritional supplements to support healthy living. The company’s products include Professional Muscular Development, a line of sports nutrition products, including Pump Fuel, ACG3, and Core Fuel; a suite of products that support weight loss and increase metabolism, such as EvoLean, Lipo Rush, and Cardio Cuts; and Doctor Health, a line of products that promote general health and well-being comprising Dr. Detox, Dr. Cholesterol, and Dr. Joints. It also sells diet, health, and sports nutrition supplements and related products. The company markets and sells its products directly to athletic facilities, gyms, and independent retailers. Bond Laboratories, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.
bond laboratories inc (BNLB) Top Compensated Officers
bond laboratories inc (BNLB) Key Developments
Bond Laboratories, Inc. announced its expansion into the Republic of Singapore.
Bond Laboratories, Inc. announced financial results for the first quarter ended March 31, 2013. For the quarter, the company reported revenue growth and positive net income. Revenue for the three months ended March 31, 2013 was $6.1 million as compared to $5.0 million for the comparable period last year, an increase of 22.3%. Net income for the three months ended March 31, 2013 was $0.6 million as compared to $0.7 million for the comparable period in 2012. Adjusted net income for the quarter ended March 31, 2013 increased 28.4% to $0.9 million from $0.7 million for the comparable quarter ended March 31, 2012. The increase in adjusted net income, while partially offset by higher selling and marketing costs principally related to ongoing international expansion efforts, was driven by both increased sales volume and improved gross margin.
Bond Laboratories, Inc. announced that the company has once again improved the terms of its existing line of credit with U.S. Bank. The new agreement increases the company's borrowing capacity by 50%, from $2,000,000 to $3,000,000 and further reduces the effective rate of interest on the credit line.
| Recently Viewed | |||
| BNLB:US | $0.11 USD | 0.00 | |
| Company | Last | Change | |
| No competitor information is available for BNLB. | |||
| View Industry Companies | |||
Industry Analysis
BNLB
Industry Average
| Valuation | BNLB | Industry Range |
| Price/Earnings | 4.1x |
|
| Price/Sales | 0.4x |
|
| Price/Book | 1.4x |
|
| Price/Cash Flow | 3.1x |
|
| TEV/Sales | 0.3x |
|
Post a JobJobs
- Orlando, FL | Consult SoftPosted: May 22
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
Sponsored Financial Commentaries
Sponsored Links
To contact BOND LABORATORIES INC, please visit www.bond-labs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.








